Trending Topic

22 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare, autoimmune neurological disorder in which peripheral nerve demyelination typically results in weakness, impaired limb sensation, fatigue and pain.1–4 CIDP may adversely affect activities of daily living, with a substantial impact on functional ability and psychological well-being.2–6 Primary treatment goals are reducing symptoms, improving functional status and maintaining long-term remission.7 The […]

Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 11th 2020

We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome Patients Treated for Up to 3 Years.’ (ABSTRACT NUMBER: 978) was presented at the virtual AES 2020, 4-8 December 2020.

Questions

  1. What are the advantages of fenfluramine compared with other anticonvulsants in patients with Dravet syndrome? (1:18)
  2. What clinical evidence led to the regulatory approval of fenfluramine in patients with Dravet syndrome? (1:58)
  3. What have the findings of the extension study taught us about the long term efficacy and safety of fenfluramine in patients with Dravet syndrome? (2:39)
  4. What safety issues should be considered when prescribing fenfluramine? (3:43)
  5. Which patients are likely to benefit most from fenfluramine and in whom is it contraindicated? (4:34)

Disclosures: Ingrid Scheffer has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of AES 2020, 4-8 December, 2020 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup